In this context, PKCα regulated CLDN1 expression via Snail- and MAPK/ERK-dependent pathways during EMT in human pancreatic cancer, shedding the light on the potential therapeutic status of PKCα inhibitors [78]. The gene discussed is PRKCA; the disease is pancreatic neoplasm.